Innovative Systems-Level Drug Design Promises More Effective Treatments for Aging and Chronic Diseases
New AI-driven research promises to revolutionize treatments for aging and chronic diseases by targeting multiple biological pathways simultaneously, offering hope for more effective therapies.
Recent advancements in artificial intelligence have revolutionized drug discovery, especially in addressing the complex biology of aging. In a collaborative effort between Scripps Research and biotechnology firm Gero, researchers have developed a machine learning model capable of identifying compounds that target multiple biological pathways simultaneously—a strategy known as polypharmacology. Unlike traditional approaches that focus on single-target drugs, this system embraces the multifaceted nature of aging, which involves an intricate interplay of numerous biological processes.
In practical application, the model successfully screened compounds that extended the lifespan of Caenorhabditis elegans, a widely used model organism in aging studies. Impressively, over 75% of the compounds tested led to lifespan extension, with one increasing lifespan by up to 74%. Such results position these compounds among the most potent longevity interventions ever observed in this model.
Dr. Peter Fedichev, CEO of Gero, explained that conventional drug discovery tends to seek highly precise, single-target solutions. However, aging's systemic and intertwined nature calls for a different approach. The integration of AI allows for the design of multi-target drugs intentionally, overcoming previous limitations that regarded such compounds as too complex or risky to develop.
Dr. Michael Petrascheck from Scripps Research highlighted that this breakthrough demonstrates AI's capacity to tackle biological questions of extraordinary complexity, enabling the development of therapies that act across multiple systems. This shift toward systemic treatment models lays the groundwork for a new generation of therapeutics aimed at extending lifespan and managing age-related diseases, which often involve the decline of multiple biological functions.
Overall, these discoveries suggest that embracing polypharmacological strategies could significantly improve the efficacy of treatments for aging and associated chronic conditions, marking a pivotal step forward in personalized and systemic medicine.
Source: medicalxpress.com/news/2025-05-drug-effective-therapies-aging-chronic
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Emerging Role of Extracellular Matrix Pathways as a Target in Pediatric Cancer Treatment
New research identifies the extracellular matrix as a promising target for developing more precise therapies for pediatric rhabdomyosarcoma, highlighting molecular differences that impact treatment strategies.
Early Mitochondrial Dysfunction and Myelin Loss Key Factors in Multiple Sclerosis Brain Damage
New research sheds light on how early mitochondrial impairment and myelin loss contribute to cerebellar damage in multiple sclerosis, offering hope for targeted therapies to protect brain health.
Challenging Decades of Beliefs: Brain Stability in Phantom Limb Experience
New research reveals that the brain's body map remains stable after amputation, challenging longstanding beliefs and opening new avenues for treatment and prosthetic development.
Study Reveals Marital Status Influences Colorectal Cancer Survival Rates
Marital status significantly influences colorectal cancer outcomes, with married patients showing higher survival rates and earlier diagnosis. A new study emphasizes the importance of targeted screening for unmarried populations.